Feed Mill Carryover Control for Type A Amprolium 25% Premix Dilution

In integrated broiler and replacement pullet operations, coccidiosis control programs rely on the dilution of a 25% amprolium hydrochloride Type A medicated article into Type C finished feed at target active concentrations of 0.0125% (125 g/ton) for prevention and 0.025% (250 g/ton) for treatment under 21 CFR 558.55. The medicated article is manufactured by dry deposition of amprolium HCl onto a mineral or plant-fibre carrier such as calcium carbonate, rice hulls, or corn cob fines; the active particle size is controlled at D90 ≤ 150 µm to limit segregation during transfer and mixing. A ribbon mixer with a working capacity of 500–2,000 kg and a paddle tip speed of 0.8–1.5 m/s is used for final feed preparation. The dilution sequence is critical: a 1:10 pre-blend is first prepared by mixing 0.5 kg of the 25% premix with 4.5 kg of ground corn or limestone for 5–8 min; this pre-blend is then discharged into the main mixer containing 995 kg of basal ration and mixed for 15 min at 20–25 rpm. Addition of the pre-blend into the mixer should occur after 30% of the main feed has been charged to avoid active material adherence to the bottom of the mixer. Batch-to-batch carryover is assessed by testing the first 50 kg of flush feed after a medicated run; amprolium concentration in the flush should fall below the limit of quantitation of the HPLC assay, typically 2 mg/kg for a method validated per USP <1225>. Flushing with ground corn at 5% of mixer capacity for 3–5 min after every medicated batch reduces cross-contamination into non-medicated rations. When the finished feed is pelleted, conditioning at 70–80°C for 30–45 s is used; steam addition must not raise final feed moisture above 14%, because excess free water causes the amprolium premix to agglomerate in the cooler and can produce fines with uneven drug distribution. Feeds containing amprolium are not compatible with bentonite-based flow agents above 2% because the clay can adsorb a portion of the active and lower assay recovery. Assay of the Type C feed is performed by HPLC with UV detection at 270 nm against a USP amprolium HCl reference standard; the acceptance criterion is 100 ± 15% of the labeled concentration with a coefficient of variation below 5% across 10 stratified samples. These limits align with FDA medicated feed CGMP expectations under 21 CFR 225 and are tighter than general feed assay tolerances because of the narrow margin between coccidiostatic activity and thiamine-displacement effects.

What Water Quality Variables Shift Amprolium Stability in Soluble Powder Dosing Systems?

Amprolium HCl is freely soluble in water, which permits preparation of drinking water medication at 60–240 mg/L from either a 9.6% w/v oral solution or a 20% w/w soluble powder. The conversion schedule is given in Table 1. In hard water with total hardness above 250 ppm CaCO₃, carbonate and bicarbonate alkalinity can raise final solution pH above 7.5, and the free-base form of amprolium precipitates as a fine haze on standing. Citric acid is therefore included in soluble powder formulations at 1.5–2.5% w/w to buffer the solution to pH 4.5–5.5; this range maintains complete dissolution at 25°C and reduces the risk of mineral salt adsorption onto galvanized water tank surfaces. Chlorinated water at residual free chlorine of 1–2 mg/L does not cause rapid assay loss over a 24 h administration period, but storage of concentrated stock solutions above 5 g/L for more than 48 h should be avoided unless protected from light and stored below 25°C. In poultry houses with proportioner pumps, the stock solution concentration is calculated as [target ppm × daily water consumption L] / [proportioner setting % × 1000]. For a target of 120 ppm, a flock consuming 1,000 L/day, and a proportioner set at 1%, the stock solution requires 12 kg of 20% soluble powder per 1,000 L of water; this is a calculation example rather than a field recommendation. Acidic water below pH 4.0 accelerates decomposition of the thiamine moiety in amprolium and is a limiting operational boundary; in such water, sodium citrate should be added to raise the pH rather than allowing prolonged contact with acidified drinking lines. Soluble powder blends are manufactured in a low-shear ribbon mixer by first screening amprolium HCl through a 60-mesh screen and blending with dextrose monohydrate for 10 min, then adding citric acid and mixing for an additional 5 min. The finished powder is filled into foil-lined sachets under ≤30% relative humidity; moisture absorption above 2% causes caking and reduces pourability in automatic medicators. Batch release includes loss on drying by USP <731>, assay by HPLC per USP <621>, and microbial enumeration by USP <61>/<62>. Soluble powder is not recommended for use through nipple drinkers with flow rates below 1 L/min because low flow can leave residual drug in the line after the medication period and cause prolonged subtherapeutic exposure.

In calf and lamb rearing operations with clinical coccidiosis outbreaks, the 9.6% w/v amprolium HCl oral drench is manufactured as a preserved aqueous solution rather than a sterile injectable product, because the oral route avoids first-pass thiamine blockade in the rumen and permits direct delivery to the intestinal crypts where Eimeria replication occurs. A representative development batch contains 96.0 g amprolium HCl, 2.0 g citric acid anhydrous, 1.0 g sodium metabisulfite, 9.0 mL benzyl alcohol, and deionized water q.s. to 1.0 L; the pH is adjusted to 4.8–5.2 with 1 N sodium hydroxide. The amprolium HCl is dissolved at 25–30°C in 70% of the final volume with continuous propeller agitation at 300 rpm; the antioxidant and preservative are added after complete dissolution to prevent localized pH shock. The solution is clarified through a 0.45 µm polyethersulfone membrane, then filled into amber high-density polyethylene bottles with a headspace of 2–3% of the fill volume. The amber container is required because amprolium is photolabile under UV exposure at 254 nm; forced degradation studies show assay loss above 5% after 72 h in clear glass under ICH Q1B light conditions. The oral drench is administered via calibrated drench gun at doses based on body weight; a common field protocol for calves is 10 mg/kg amprolium HCl daily for 5 consecutive days, although published data for this specific configuration is limited and the label of the reference product should be consulted for jurisdictional dose limits. Stability of the aqueous solution is limited by benzyl alcohol oxidation; the product is assigned a 24-month shelf life at ≤25°C with tight container closure. Residual benzyl alcohol content is monitored by GC headspace per USP <467>; the acceptance limit is 90–110% of the labeled amount. In multi-dose farm packaging, the bung must be vented with a sterile air inlet to prevent vacuum collapse during dose withdrawal; silicon tubing used with the drench gun should be flushed with warm water after each use to prevent crystal deposition at the nozzle.

When a 20 mg Amprolium Tablet Must Pass USP <905> Without a Preceding Granulation Step

Because amprolium HCl is fluffy and tends to adhere to dies and punches, direct compression into 20 mg tablets for individual small ruminant therapy requires careful control of API particle size. A development formulation contains 20% w/w amprolium HCl, 73% w/w microcrystalline cellulose Ph-102, 5% w/w croscarmellose sodium, 1% w/w colloidal silicon dioxide, and 1% w/w magnesium stearate. The API is screened through a 40-mesh sieve and pre-blended with an equal mass of microcrystalline cellulose in a V-blender for 10 min at 25 rpm; the remaining microcrystalline cellulose and croscarmellose are added and mixed for 15 min, and the magnesium stearate is finally added with only 3 min additional mixing to avoid excessive lubrication. The blend is compressed on a 16-station rotary tablet press using 6 mm standard concave punches at a compression force of 8–12 kN; tablet hardness is held at 60–90 N, and friability is ≤1.0% after 100 revolutions per USP <1216>. The disintegration time in distilled water at 37 ± 2°C must not exceed 15 min per USP <701>; croscarmellose sodium is pre-dried at 60°C if ambient relative humidity exceeds 60%, because moisture activation of the disintegrant causes premature swelling and lowers tablet hardness. Content uniformity is evaluated on 10 tablets per USP <905>; the acceptance value must be ≤15.0, and a typical direct compression batch with the specified particle size achieves 5–8. Dissolution testing in 900 mL of 0.1 N hydrochloric acid at 50 rpm using Apparatus 2 per USP <711> is used as a discriminating method; the target is ≥80% release at 30 min, but published data for this specific amprolium tablet configuration is limited and should be established during product development. The tablets are packed in amber blister packs with a desiccant canister; the API is hygroscopic above 70% relative humidity, and moisture ingress above 2% w/w causes surface pitting and loss of content uniformity. Because direct compression is sensitive to flow variations, the blend must be monitored for bulk density with a target of 0.50–0.65 g/mL and tapped density per USP <616>; a Carr index above 30 indicates insufficient flow for high-speed compression and requires adjustment of the colloidal silicon dioxide level to 1.5% w/w. This dosage form is not a standard FDA-approved commercial veterinary tablet; it is compounded under the extra-label use provisions of 21 CFR 530 in the United States or equivalent veterinary compounding allowances in other jurisdictions.

In fluidised-bed processing of amprolium hydrochloride top-dress granules, strict control of spray rate and product temperature is required because the API dissolves partially in the binder solution and can migrate to the particle surface during drying, producing granules with a surface-enriched active layer that dissolves too rapidly in the rumen. A representative granulation batch uses 20% w/w amprolium HCl, 75% w/w lactose monohydrate, 4% w/w povidone K30, and 1% w/w talc. The binder solution is prepared as 5% w/v povidone K30 in deionized water and sprayed onto the fluidised powder bed at 10–15 g/min for a 2 kg bed; inlet air temperature is maintained at 55–65°C, and product temperature is held at 32–38°C to avoid thermal degradation of the thiamine ring. Atomising air pressure at the binary nozzle is set at 1.2–1.5 bar; droplets above 20 µm produce overwet beds that defluidise, while droplets below 8 µm dry prematurely and fail to agglomerate. The granulation end-point is determined by a moisture balance, with loss on drying of 1.0–1.5% w/w per USP <731>. The dried granules are milled through a 16-mesh screen and the 250–425 µm fraction is collected for top-dress use; fines below 125 µm are recycled into the next granulation batch to maintain yield. The final granules contain 200 mg/g amprolium HCl and are administered as a top-dress on starter grain for individually housed calves at a dose of 10 mg/kg body weight once daily for 5 days; this application is a compounded veterinary preparation rather than a registered Type A medicated article unless specifically approved in the jurisdiction. Granule stability is evaluated by HPLC assay and water activity measurement; water activity below 0.6 at 25°C prevents microbial growth and granule hardening. Dissolution from the granule surface is tested using a modified USP <711> method in 900 mL water at 50 rpm; more than 85% release at 15 min indicates a surface-enriched granule, while release below 70% at 30 min suggests overgranulation or lactose crystallisation during drying. The product is packaged in foil-lined multi-wall paper bags under nitrogen; residual oxygen in the headspace must be below 5% to limit oxidative discoloration over an 18-month assigned shelf life.

Injectable Amprolium HCl: Lyophilisation versus Autoclave Terminal Sterilisation Trade-Offs

Although amprolium HCl is not recognised as a standard parenteral veterinary medicinal product in most jurisdictions, its development as an injectable solution is compounded extra-label or prepared as an emergency hospital formulation. The API is freely soluble in water, enabling a 5% w/v solution without co-solvents; the pH of a plain aqueous solution is approximately 5.5. Terminal sterilisation by autoclave at 121°C for 15 min is technically feasible only if the solution is buffered to pH 4.5–5.0 with citric acid and sodium citrate, because alkaline pH accelerates thiazole ring opening. A representative formulation for thermal stability screening contains amprolium HCl 50.0 g/L, citric acid monohydrate 2.0 g/L, sodium citrate dihydrate 3.0 g/L, and sodium chloride for isotonicity at 290–310 mOsm/L. The solution is sparged with nitrogen before filling into amber vials; dissolved oxygen is reduced to ≤1.0 mg/L to limit oxidative degradation. Autoclaved vials should be sampled for assay and related substances by HPLC per USP <621>; a stability-indicating method with a C18 column and ion-pair reagent at 270 nm separates amprolium from the ring-opened degradation product. Published data for amprolium HCl stability after autoclaving is limited, so a forced-degradation bracketing study at 80°C for 8 h is required before committing to terminal sterilisation. If assay loss exceeds 5% or total related substances exceed 2%, sterile filtration through a 0.22 µm double-sterilising PVDF cartridge at ≤25°C is substituted. Sterile filtration imposes a bioburden limit of ≤10 CFU/100 mL before filtration per USP <71> and requires use in an ISO 5 laminar-flow area; the final solution is filled into Type I glass vials and stoppered under grade A conditions. The injectable route must not be used in food-producing animals without a withdrawal period assigned by a licensed veterinarian; the absence of published residue depletion data for parenteral amprolium is a critical trust boundary. In hospital practice, a 5 mg/kg compounded preparation has been described, but published data for this specific configuration is limited, and no global harmonised standard exists for an amprolium injection monograph.

For compounding pharmacies dispensing unit-dose oral therapy to small ruminants and zoo species, hard gelatin capsule filling of amprolium HCl at 25 mg unit doses is used primarily when liquid drenching is impractical. The API is highly hygroscopic and must be pre-dried at 60°C for 4 h if moisture content exceeds 0.5%, then immediately blended in a low-shear tumble blender with pre-dried lactose monohydrate at 25°C and ≤30% relative humidity. A representative fill formula contains 25 mg amprolium HCl, 125 mg lactose monohydrate, 3 mg colloidal silicon dioxide, and 1 mg magnesium stearate per capsule. The silicon dioxide is first passed through a 60-mesh screen and blended with the API for 5 min to reduce electrostatic clinging, then lactose is added and mixed for 15 min; lubricant is added last for 2–3 min to avoid forming hydrophobic films on the API particles. The blend is filled into size 3 hard gelatin capsules using a semiautomatic tamping pin machine; fill weight is controlled to ±5% of the target, and weight variation is assessed on 20 capsules per USP <905>. The tamping pin force is calibrated to 1.5–2.0 kg; higher forces can cause particle attrition and increase the surface area of the API, leading to rapid moisture uptake and capsule brittleness. Capsules are stored in amber plastic vials with silica gel and cotton; the gelatin shell must remain below 14% moisture to prevent cross-linking with amprolium degradation by-products. Dissolution testing for compounded capsules is not harmonised globally; a development method in 900 mL water at 50 rpm per USP <711> with sampling at 30 min is used to verify release. Amprolium HCl capsules are intended for oral administration in goats, sheep, and exotic ruminants; dose calculations are based on 10 mg/kg but should be adjusted by the prescribing veterinarian according to the specific Eimeria challenge and the animal’s thiamine status. Because amprolium acts as a thiamine antagonist, chronic dosing above 3–5 days in species with marginal thiamine intake can induce polioencephalomalacia; this risk is the principal operational boundary for capsule use. No commercial registered amprolium capsule product exists in the United States, and this compounded form falls outside the broad-label medicated feed approvals under 21 CFR 558.55, requiring a valid veterinarian-client-patient relationship and state pharmacy compliance.